Avacta Therapeutics
  • About
  • Our Science
  • Pipeline
  • News
  • Investors
  • Careers
  • Contact
  • About
    • About Avacta
    • Leadership
    • Intellectual Property
  • Our Science
    • Our Science
    • 1st Gen
    • 2nd Gen
    • 3rd Gen
    • Partners
    • Clinical trials
  • Pipeline
  • News
  • Investors
    • Investors
    • Key info
    • Corporate Governance
    • Resources
    • Publications
    • Share price
    • Events
    • Research
  • Careers
    • Job vacancies
    • Benefits of working at Avacta
  • Contact
  • About
    • About Avacta
    • Leadership
    • Intellectual Property
  • Our Science
    • Our Science
    • 1st Gen
    • 2nd Gen
    • 3rd Gen
    • Partners
    • Clinical trials
  • Pipeline
  • News
  • Investors
    • Investors
    • Key info
    • Corporate Governance
    • Resources
    • Publications
    • Share price
    • Events
    • Research
  • Careers
    • Job vacancies
    • Benefits of working at Avacta
  • Contact
Home News Therapeutics Page 3
filter by: view all | Avacta Academy | Blogs | Diagnostics | Investors | Podcasts and Videos | R&D Spotlights Series | Therapeutics

Therapeutics

24 Feb 2026

Avacta’s pre|CISION Mechanism for Payload Delivery Shows Key Advantages Compared to an Antibody Drug Conjugate in Innovative AI-Driven Analysis

Investors | Therapeutics
09 Feb 2026

Avacta appoints Francis Wilson as Chief Scientific Officer 

Investors | Therapeutics
03 Feb 2026

Avacta announces two key clinical updates to its faridoxorubicin program

Investors | Therapeutics
21 Jan 2026

Avacta Announces U.S. Food and Drug Administration Clearance of the Investigational New Drug (IND) Application for the Second pre|CISION® Medicine, FAP-Exatecan (AVA6103)

Investors | Therapeutics
20 Jan 2026

Year-end trading update

Investors | Therapeutics
18 Dec 2025

Research & Development Spotlight Series, Episode 13

Podcasts and Videos | R&D Spotlights Series | Therapeutics
18 Dec 2025

Avacta reports new pharmacology data for FAP-Exd (AVA6103)

Investors | Therapeutics
17 Dec 2025

Faridoxorubicin (AVA6000) Phase 1b cohort demonstrates clinically meaningful tumor shrinkage in patients with salivary gland cancers

Investors | Therapeutics
08 Dec 2025

Avacta Announces the Preliminary Clinical Data in the Faridoxorubicin Phase 1b Trial in the Salivary Gland Cancer Cohort

Investors | Therapeutics
25 Oct 2025

Avacta presents first preclinical data from dual payload pre|CISION® medicines at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets

Investors | Therapeutics

Posts navigation

Older posts
Newer posts
Avacta Therapeutics
  • Terms of Use
  • Terms & Conditions
  • Privacy Policy
  • Intellectual Property
  • Corporate Responsibility
  • Contact Us

Avacta Group plc

Scale Space,  White City
Imperial College Campus
58 Wood Lane
London
W12 7RZ

+44 (0)20 3911 0353

Investor Enquiries

Cohesion Bureau

 

Email

Twitter | Linkedin

©2026 Avacta Therapeutics. Registered company no. 06605196.